Raned Competitors

At Jabil (NYSE: JBL), we are proud to be a trusted partner for the world's top brands, offering comprehensive engineering, supply chain, and manufacturing solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe.

ProGreen Synthetic Turf Systems is the nation's leading supplier of artificial grass for use in lawns, dog runs, putting greens, athletic fields, playground surfaces and more. All of our products are 100% made in the USA from start to finish in our own manufacturing facilities.

BIOGENERA SpA is a company operating in the biotechnology pharmaceutical sector, specialising in the research and development of new DNA-based patient-specific biotechnological medicines for the treatment of serious pathologies. Founded in 2008, with its headquarters in Bologna, BIOGENERA SpA has a multidisciplinary team of researchers and is supported by numerous University partnerships ( in particular, the University of Bologna) and other companies of the pharmaceutical sector. Mission To create new treatments for diseases as yet considered incurable, focusing specifically on paediatric tumors. Thanks to the exclusive MyGeneraTM platform, BIOGENERA is capable of rapidly identifying and developing new patient-specific medicines aimed at every therapeutic target made up of single mutated genes, considered causative for a pathology. MyGeneraTM permits, with a unique and innovative approach, the identification and development of gene-specific molecules for absolutely patient-specific DNA-cures. BIOGENERA SpA è una società che opera nel settore delle biotecnologie farmaceutiche, specializzata nella ricerca e di sviluppo di nuovi farmaci biotecnologici personalizzati a DNA per il trattamento di patologie gravi. Costituita nel 2008, con sede a Bologna, BIOGENERA SpA conta su un team multidisciplinare di ricercatori italiani e si avvale di numerose partnerships con Università (in particolare con l’Università di Bologna) e ditte del settore farmaceutico. La nostra mission è generare nuovi trattamenti per malattie ad oggi incurabili, con un focus specifico sui tumori pediatrici. Grazie all’esclusiva piattaforma MyGeneraTM, BIOGENERA è in grado di identificare e sviluppare rapidamente nuovi farmaci specifici mirati ad ogni bersaglio terapeutico costituito da un singolo gene mutato considerato causale per una patologia.